In this study, the emphasis is placed on a strategy for enhancing the drug/carrier interaction for improved drug solubility, drug-loading capacity, self-emulsification and stability.Preliminary solubility of L294 was determined in various oils, surfactants and cosurfactants. A ternary phase diagram was constructed to identify the self-emulsifying region for the selected systems, using series concentrations of Labrafac PG, Labrasol and Transcutol HP. Self-emulsifying properties, particle size, polydispersibility, and zeta potential were studied after dilution of formulations in water.The results demonstrated the development of a self-emulsifying formulation of L294 in liquid form, which upon contact with aqueous media spontaneously forms a clear nanoemulsion having a small droplet size (around 100 nm). The zeta potential of the selected SEDDS formulation was between −11.09 and −20.50 with a viscosity around 40-60 cP. The optimum formulation consisted of a mixture of Labrafac PG, Labrasol and Transcutol HP.The L294 showed extremely low water solubility (0,006 mg.mL -1 ), and when formulated in SEDDS, its solubility increased over than 33,000 fold.This study demonstrate that SEDDS can be considered as a very good candidate to optimize the peroral administration of L294.
INTRODUCTION
LASSBio 294 is a novel cardioactive Nacylhydrazone compound, 3,4-methylenedioxybenzoyl-2-thienylhydrazone (L294). [1; 2] This compound has been described as a potent cardiac inotropic agent with vasodilator properties. [3; 4] L294 was found to improve intracellular Ca 2+ regulation [2; 5; 6] and prevent myocardial infarction induced by cardiac dysfunction, which could potentially prevent heart failure. [7] In addition, L294 also promoted vasodilation in aortic rings, mediated by the guanylatecyclase/cyclic guanylate monophosphate pathway. [6; 8] The L294 drug is rapidly absorbed and eliminated after oral administration. [9] Following a single 10 mg oral dose administration, mean peak plasma levels of 550 ng/ml are attained in about 1 h. Based on in silico data, L294 should be classified in the class II category under the biopharmaceutical classification system (BCS), i.e., it has good permeability through biological membranes, but exhibits low aqueous solubility. The rate of absorption of any drug is mainly controlled by its dissolution rate in gastrointestinal fluids, especially insoluble hydrophobic drugs. L294 alone have a very low bioavailability, due to its poor solubility in water combined with an insufficient dissolution rate. [9] L294 is a weak acid (pKa predicted properties is 10.8) -it is practically insoluble in water 0.006 mg.g -1 (personal data). These parameters make L294 a perfect molecule for the development of SEDDS, aiming the improvement of its bioavailability.
Poorly water-soluble drug candidates are often presented to formulators with considerable technical challenges. A significant number of drugs suffer from the problem of low oral absorption, [10] [11] [12] and thus poor oral efficiency. Different strategies have been investigated to enhance the bioavailability of poorly absorbed drugs in order to increase their clinical efficacy when administered orally. [13] Innovative lipid-based formulations, such as self-emulsifying drug delivery systems (SEDDS), have been extensively described as effective delivery systems due to their proven ability to enhance bioavailability of lipophilic drugs. [12; 14-17] SEEDS are drug delivery systems based on a mixture of oils, surfactants, co-solvents and drugs, which results in entropy-favoured spontaneous emulsification on in situ exposure, and can sometimes emulsify under conditions of gentle agitation, similar to those that would be encountered in the gastrointestinal tract. [13; 18-21] The ability of SEDDS to improve oral bioavailability has been shown for curcumin, [22] mitotane, [23] mefenamic acid, [24] Valsartan, [25] to improve the oral absorption of carvediol, [11] inhibition of human efflux transporter ABCC2, [26] and transformation of the crystalline form of the drug to the amorphous form in the SEDDS. [16] SEDDS are among the methods used to improve the oral bioavailability of poorly soluble drugs by presenting and maintaining the drug in a dissolved state, in small droplets of oil, and all over its transit through the gastrointestinal tract. [16; 27; 28] SEDDS can improve oral bioavailability by minimising the effect of pH on drug absorption, increasing drug solubilisation, in which the water-insoluble drug is usually dissolved in the oil phase, therefore enhancing permeation across the intestinal membrane through a wide distribution in the gastrointestinal tract, due to its small droplet size. [29] [30] [31] The potential advantages of the SEDDS include 100% drug entrapment capacity, physically stable formulation, [13] with no dissolution step required, and also providing protection against gastric degradation. [13; 32] Soft gelatin capsules containing SEDDS readily disperse in the stomach to form a fine emulsion; [33] in this case, gastrointestinal motility can provide the agitating effect necessary for emulsification. [33] While the primary mechanism by which SEDDS formulations are thought to improve drug absorption is through elimination of the need for pre-absorptive drug solubilisation in the gastrointestinal tract, other mechanisms may include protection from chemical and enzymatic degradation localised in the aqueous environment of the gastrointestinal tract and promotion of lymphatic drug transport, bypassing the hepatic first pass effect. [13; 15; 19] In the process of developing SEDDS formulations, different compositions of oils, surfactants and cosurfactants have to be evaluated for identifying the best self-emulsifying region of the system.
[34] Self-emulsified formulations are a clear dispersion, which should remain stable on dilution in order to make the hydrophobic drugs remain in solubilised form until absorption. The present work aims on the design, development and characterisation of a SEDDS formulation loaded with L294. Moreover, this work describes the ability to form nanoemulsion characterisation of formulations on the nanoemulsifying area in the phase diagram.
MATERIAL AND METHODS

Chemicals
Labrasol, Transcutol HP, Lauroglycol 90, Labrafac PG, Maisine 35-1, LabrafacLipophile WL 1349, Capryol 90, Peceol, and Labrafil M1944CS were generously donated by Gattefossé (France). Cremophor EL and Cremophor RH40 were received from BASF (Germany). Castor oil, Tween 20 and Tween 80 were obtained as gift samples from Croda (Brazil). Other oils, surfactants and cosurfactants were of pharmaceutical grade. All other chemicals and solvents were of analytical grades. L294 was 3,4-methylenodioxybenzoyl-2-thienylhydrazone and was used as the model drug. Its molecular structure and physicochemical properties are shown in Fig. 1 and Table 1 , respectively.
Excipient screening
L294's solubility in oils (Table 2) , surfactants (Table 3 ) and cosurfactants (Table 4) was individually determined in shake flasks. Briefly, an excess amount of L294 (0.5 g) was added to 50 mL Erlenmeyer flasks containing 25 mL of each tested vehicle. The flasks were homogenised in a vortex mixer (Vortex-2 Genie, Scientific Industries, USA) for 2 min, then, the flasks were kept under mild constant agitation for 48 h at 37°C in an orbital shaker (Dubnoff 304-D, Nova Etica, Brazil). After equilibrium was achieved, the samples were centrifuged at 3,500g for 15 min (Thermo Scientific Sorval Legend Mach 1.6R) for non-solubilised drug removal. The supernatant was collected, diluted in a proper solvent and analysed at 318 nm using an UV-VIS spectrophotometer (PharmaSpec UV-1700, Shimadzu, Japan) to access the amount of solubilised L294. Pure water was used as a control. The experiment was performed in triplicate, and the results were represented as a mean value (mg.g 
Construction of phase diagrams
The selected oil (Labrafac PG), surfactant (Labrasol), and cosurfactant (Transcutol HP), based on preliminary screening studies, were used to develop phase diagrams. The ternary phase diagram was constructed in the presence of the drug to identify the self-emulsifying region and the ideal proportions of eachexcipient. To construct the phase diagram, different liquid SEDDS formulations (pre-concentrate) were prepared by solubilisation of L294 in the mixture of excipients, using mild magnetic stirring at room temperature for a maximum period of three hours to obtain a clear solution. The formulations were left standing for 24 h to achieve equilibrium and then stored at room temperature. The ternary phase diagram was plotted, with the composition of oil, surfactant and cosurfactantfixed as each vertices of the triangle. Different oil/surfactant/cosurfactant mixtures were prepared according to the proportion of each point of the triangle.
The level of L294 was fixed at 0.2% w/w of the vehicle. Six different series of the SEDDS (Table 5) were prepared with varying concentrations of oil (5-30%), surfactant (40-80%) and cosurfactant (5-30%). The volume ratio of diluent to preconcentrate SEDDS formulations was fixed in 100:0.1, considering the volume (≅ 100 mL) of the gastric fluid.
[36] 
Characterisation and evaluation of L294-loaded SEDDS
SEDDS formulations were examined for nanoemulsion formation after diluting with pure water. Each SEDDS formulation (0.1 mL) was introduced into 100 mL of pure water in a volumetric flask at 37°C. The contents were gently mixed and were kept for 2h at 37ºC. The spreadability tendency to spontaneously emulsify and progress the emulsion droplets were observed. The pre-concentrates that could selfemulsify under gentle agitation and dilution were identified in the phase diagram. All formulations were characterised for droplet size, ζ-potential and visual observation after dilution in water. Viscosity measurements and visual observations were taken for the pre-concentrates.
Viscosity
Viscosity can be used as a physical characterisation parameter. Thus, viscosity was measured using the Vibration method, placing 10 mL of undiluted formulation SEDDS in the viscometer SV-10 (A&D Co., Japan). The measures were determined at room temperature by detecting the driving electric current necessary to resonate the two sensor plates at a constant frequency of 30Hz and amplitude of less than 1 mm.
Self-emulsification and precipitation assessment
The SEDDS formulations were categorised based on appearance (transparency) and apparent stability of the resultant nanoemulsions. Visual assessment was performed by dropwise addition of the SEDDS into of purified water in a glass vial at room temperature. The contents were gently stirred, immediately kept standing against light, and were observed for assessment for selfemulsification efficiency, transparency, phase separation and precipitation of L294. Precipitation was evaluated by visual inspection of the resultant nanoemulsion after 24 h. These formulations were categorised as clear (transparent or transparent with bluish tinge), not clear (turbid), stable (with precipitation) or unstable (without precipitation). SEDDS with clear or slightly bluish appearances were classified as nanoemulsions. 
Droplet size analysis and ζ-potential
The droplet size and polydispersity index (PDI) of the SEDDS formulation were determined using the dynamic light scattering (DLS) technique -DLS at 90° fixed angle using a Zetasizer Nano ZS (Malvern Instruments, UK). Each formulation was diluted with purified water before analysis. This equipment was also used for ζ-potential measurement and operated at a 25°C, 23 Vcm -1 electric field intensity. All studies were repeated three times and the values of the diameters and intensity were used.
The droplet size was measured as the mean diameter using the Stokes-Einstein equation. It was also described in terms of intensity and number distributions. The intensity distribution is proportional to the sixth power diameter (Iαd 6 ) and amplifies the signal by showing all diameters in the sample. Number distribution is proportional to the first power diameter (Nαd) and shows the predominant diameters. The polydispersity (PDI) reflects the dispersion of the particle diameters. The zeta potential values were calculated according to the Smoluchowski equation.
RESULTS
Excipient selection
The selection of oil, surfactant or cosurfactant was governed by previous studies of excipient screening (personal data). The comparative solubility studies of L294 in the oil, surfactant and cosurfactant selected are reported Fig. 2 . The aqueous solubility of L294 was about 0.006 mg.g -1 , indicating that it was poorly water-soluble. L294 has low miscibility in the assayed oils (approximately 1 mg.g . However, the solubility in Labrafil M1944CS (HLB 4), Capryol 90 (HLB 6), and Lauroglycol 90 (HLB 5) was less than 2.5 mg.g -1 . Solubility of L294 in the cosurfactantTranscutol HP showed good solubilising capacity (18.5 mg.g -1 ), and poor solubility in propylene glycol (less than 3.5 mg.g -1 ). Amongst the various solvents investigated for equilibrium solubility studies, Labrafac PG, Labrasol and Transcutol HP were selected for construction of ternary phase diagrams.
The lipid is a more important ingredient of the SEDDS formulation [15] ,among the used oils, Maisine 35-1 and Labrafac PG showed maximum and minimum solubility for L294. Maisine (HLB = 4) had more strength to solve L294 than did Labrafac(HLB = 2). However, Labrafac PG exhibited good emulsification properties with all surfactants tested (personal data). Therefore, lipids can not only solubilise large amount of lipophilic drugs or facilitate self-emulsification but also enhance the fraction of lipophilic drugs transported via the intestinal lymphatic system, thereby increasing its absorption from the GI tract. [15; 37; 38] A surfactant is to provide the essential emulsifying characteristics to SEDDS, [15] making it possible for large amounts of drug compounds to get dissolved into the system.
[18] Surfactants, being amphiphilic compounds, invariably dissolve larger amounts of the hydrophobic drug. The two issues that govern the selection of a surfactant involve the hydrophilic-lipophilic balance (HLB) and safety. [15] The hydrophobically assembled micelles usually consist of amphiphilic compounds that have distinct hydrophobic and hydrophilic domains. [39] Upon exposure to an aqueous medium, the amphiphilic molecules spontaneously self-assemble into supramolecular core/shell structures, and water-insoluble drugs can be loaded into the hydrophobic cores. [40] The HLB of a surfactant provides important information on its potential and utility in the formulation of SEDDS. [15] For attaining high emulsifying performance, the emulsifier involved in the formulation of SEDDS should have high HLB and high hydrophilicity for immediate formation of o/w droplets and rapid spreading of formulation in aqueous media. [15] Non-ionic surfactants are generally considered for pharmaceutical applications and nanoemulsion formulation since these are less toxic [41] than ionic surfactants, and they are accepted for oral ingestion.
[20; 42; 43] As required for SEDDS development, surfactants of high HLB value have a high self-emulsifying capability in the aqueous phase. [44] HLB values in the range of 12-16 favour the nanoemulsion formation. [45] Lipophilic surfactants with an HLB of less than 10 are capable of promoting some emulsification of the oil, but the resulting emulsions are normally too crude (in terms of size) to be useful. [45] Hydrophilic surfactants with an HLB of more than 10 are far superior at these, providing fines and uniform emulsion droplets that are more likely to empty rapidly from the stomach. [46; 47] Thus, for the present study, Labrasol was used as surfactant having, an HLB value equal to 14. Labrasol, a surfactant of medium length alkyl chain, showed higher drug solubility, and is a macrogol glyceride that is able to form microemulsions in GI fluids. [48] Moreover, Labrasol was reported to enhance the intestinal absorption of drugs, [49; 50] and several studies describesLabrasolas an enhancer of oral bioavailability of various drugs, such as insulin, [51] vancomycin, [49] ezetimibe, [14] ganciclovir, [5 2] buparvaquone, [53] flurbiprofen, [54] nimodipine, [55] and fizetin. [56] Surfactants form a layer around the emulsion droplets and hence reduce the interfacial energy, as well as provide a mechanical barrier to coalescence. [47] The addition of a cosurfactant in the formulation containing surfactant was reported to improve dispersibility and drug absorption from the formulation, in addition to reducing interfacial tension and the formation of mechanical barriers to coalescence. [20; 44] Cosurfactants increase surfactant emulsification by penetrating the interfacial surfactant monolayer and their structure and chain length affect their performance. [57; 58] Therefore, it seems that increasing surfactant having a high HLB concentration, the drug's solubility increased. Transcutol has been used as an effective solubilizing agent and a permeability enhancer in emulsifying systems. The blending of Transcutol with the Labrasol mainly helps in improving the emulsification ability of Labrasol, and Kim et al [59] has already used this approach. Furthermore, Labrafac, Labrasol and Transcutol are known bioavailability enhancers. 
Ternary phase diagrams
The phase diagram plays an important role in studying the phase behaviour of prepared nanoemulsions. [44] Phase diagrams are normally constructed with the oil phase, surfactant or mixture of surfactant and cosurfactant, and the aqueous phase, which will reveal the regions of liquid crystal, nano/microemulsion and coarse emulsion. [33; 42] In SEDDS, the primary means of assessment of self-emulsification is visual evaluation, and the self-emulsification efficiency can be estimated by determining the droplet size (number diameter and intensity). The visual test is a measure of an apparent spontaneity of emulsion formation. In the dilution study, visually there were no significant differences found in the selfemulsifying performance among series diluted in the same dissolution medium (water).
Oil, surfactant and cosurfactant were selected based on their drug solubility capacity, hydrophiliclipophilic balance (HLB) values and ability of emulsion formation and biopharmaceutical properties. These ternary phase diagrams were constructed in the presence of L294 to identify the self-emulsifying regions and optimise the concentration of oil, surfactant and cosurfactant in the SEDDS formulation. The effect of the aqueous phase was overlooked for simplicity's sake, and only oil, surfactant and cosurfactant components concentration were used to identify the selfemulsifying region, as described in similar studies.
[36; 47; 62] Fig . 3 describes the phase diagrams of the self-emulsifying systems loaded with L294 andcomposed byLabrafac PG oil, Labrasol surfactant and Transcutol HP cosurfactant. The shaded area, corresponding to oil (between 5-30%), surfactant (between 40-80%) and cosurfactant (between 5 and 30%), represents the efficient spontaneous emulsion region after dilution. It was observed that emulsification efficiency was good when Labrafac concentrations were higher than 5% and less than 30% of the SEDDS formulation. However, increasing Labrasolconcentration up to approximately 80%,increased the self-emulsification process spontaneity.
Furthermore, increasing the cosurfactantconcentration decreases the selfemulsification process spontaneity. As cosurfactants have very little effect on reducing the interfacial tension, they help the surfactants to reduce the interfacial tension. [47; 63] Dispersions resulting from water dilution showed to be clear without precipitation and/or phase separation, nor showed signs of cloudiness and were bluish-transparent. All of the liquid SEDDS formulations form clear and slight bluish nanoemulsions in less than 1 min when diluted with the distilled water medium. A desired ratio of components was further determined by investigating the droplet size distributions.
Physicochemical properties of liquid SEDDS
The liquid SEDDS series (A-F, Table 5 ) showedviscosity values 16 and 63 cP, while the droplet size of the resultant formulations after dilution was found to be between 82 and 493 nm (number). PI was less than 0.35, indicating that the studied self-emulsifying systems had a narrow size distribution. [64] The results of ZP ranged from -5.00 to -21.70 mV. The resultant charge was negative probably due to both surfactants used in the formulation. Based on these results, formulations some (Table 6 ) have been selected as the most promising nanoemulsion.
The physicochemical properties of the selected formulations were examined as a pre-concentrate, showed viscosity results less than 65 cP, which indicated formulations with good operability. [63] The viscosity of the formulations increases when the concentration of surfactant is above 65%; however, there is no statistical correlation between viscosity and droplet size. It was expected that the increasing cosurfactant concentrations resulted in smaller droplets formation, since the cosurfactant acts on the reduction of the curvature angle of droplet formation, [65] but in this case, low concentrations of cosurfactant (5-15%) result in a droplet size of around 100 nm.
The PI increases with increases in the oil concentration. Most formulations (76%) have a DS in the range of 100-200 nm, while a smaller proportion of formulations (18%) had a DS of less than 100 nm, and only 6% of formulations exhibited a DS above 200 nm. When one increases the surfactant concentration, the result is a decrease on the mean droplet size. This could be explained by the oil droplet stabilisation since the surfactant molecules would be present at the oilwater interface. [25; 34; 45] SEDDS selected series, examined as a preconcentrate, showed viscosity results less than 65 cP, which indicated formulations with good operability. [63] The viscosity of the formulations increases when the concentration of surfactant is above 65%; however, there is no statistical correlation between viscosity and droplet size. It was expected that increasing concentrations of cosurfactant would also result in the formation of smaller droplets because it reduces the angle of the curvature during droplet formation, [65] but in this case, low concentrations of cosurfactant (5-15%) result in a droplet size of around 100 nm.
Viscosity assessmentis necessary on SEDDS formulation for its physical characterisation and also to understand the control of its stability. It is also crucial in determining its ability to be filled in hard or soft gelatin capsules.
[30] If the system has very low viscosity, there is an enhanced probability of leakage from the capsule and the system with very high viscosity may have problems with operability. [30; 66] The droplet size of SEDDS is a critical factor in self-emulsification performance because it determines the rate and extent of drug release, as well as absorption, [67] providing enhancing drug bioavailability.
[35] Droplet size under 100 nm is considered desirable. [45; 64] Microemulsions with droplets size under 200 nm were considered acceptable according to Jain et al [68] . A smaller droplet size would bring forth a larger interfacial surface area for drug absorption; [69] therefore, a faster release rate could be achieved. [25; 34; 37; 70] PI value is a measure of the width of size distribution and ranges from 0 to 1. [64] The values near zero indicate a monodispersed particle population, whereas values >0.5 signify a very broad size distribution. [64] PI <0.1 indicates a homogenous population, while a PI >0.3 indicates a higher heterogeneous dispersion. [71] The PI for all the stable SEDDS formulations was within the acceptable limits. [10] The polydispersity value is inversely proportional to the uniformity of droplet size in the formulation. [25; 72] The charge of the SEDDS droplets should be assessed, [73; 74] along with polarity of droplets is also a quite important factor at the characterisation of emulsification efficiency. [44; 75] Zeta-potential indicates the degree of repulsion between adjacent particles with the same surface charge in dispersion, and its value can relate to the stability of nanoemulsion in SEDDS. In this particular case, the SEDDS emulsion stability would be granted by a higher zeta potential, either positive or negative. If the potential is low enough, the attraction between droplets would exceed repulsion and the emulsion would break and/or flocculate. [44] Therefore, nanoemulsions from SEEDS with high zeta potential are electrically stabilised. [37; 44] 
CONCLUSION
In this study, the emphasis was placed on a strategy for enhancing the drug/carrier interaction for improved L294 solubility, L294-loading capacity, self-emulsification and stability of formulation. SEDDS components were selected based on biopharmaceutical properties and L294 solubility. A L294 SEDDS formulation composed by Labrafac PG (oil) and Labrasol (surfactant) with Transcutol HP (cosurfactant) was effectively developed. A small optimisation was performed based on droplets size, polydispersity, viscosity, and solubility. After extensive optimisation and evaluation, the developed L294-SEDDS were characterised for various qualitative and quantitative attributes. L294-SEDDS was shown to be monodispersed droplets with a size of 100 ± 10 nm, exhibiting negative ζ potential. The optimised L294 SEDDS needed a surfactant content of more than 65% and yielded nanoemulsion of a mean globule size of around 100 nm. This work reported the L294 self-emulsifying systems development in liquid form, in which in contact with water or aqueous media forms a nanoemsulsion without the need for external energy. The L294 showed extremely low water solubility (0.006 mg.mL -1 ), and when formulated in SEDDS, its solubility increased over than 33,000 fold. Further studies should be performed on the evaluation of L294 loaded in SEDDS in vivo bioavailability.
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